Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel. more
Time Frame | TEVA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.19% | -0.25% | 0.06% |
1-Month Return | -3.04% | 2.64% | 3.07% |
3-Month Return | 15.17% | -0.87% | 4.44% |
6-Month Return | 55.21% | 7.88% | 15% |
1-Year Return | 116.67% | 13.56% | 26.61% |
3-Year Return | 58.54% | 21.42% | 33.33% |
5-Year Return | 76.06% | 71.6% | 101.55% |
10-Year Return | -65.88% | 181.82% | 234.58% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 16.89B | 16.66B | 15.88B | 14.93B | 15.85B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.64,"profit":true},{"date":"2021-12-31","value":94.02,"profit":true},{"date":"2022-12-31","value":88.38,"profit":true},{"date":"2023-12-31","value":93.84,"profit":true}] |
Cost of Revenue | 9.35B | 8.93B | 8.28B | 7.95B | 8.20B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.53,"profit":true},{"date":"2021-12-31","value":88.59,"profit":true},{"date":"2022-12-31","value":85.04,"profit":true},{"date":"2023-12-31","value":87.7,"profit":true}] |
Gross Profit | 7.54B | 7.72B | 7.59B | 6.97B | 7.64B | [{"date":"2019-12-31","value":97.55,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.3,"profit":true},{"date":"2022-12-31","value":90.27,"profit":true},{"date":"2023-12-31","value":98.96,"profit":true}] |
Gross Margin | 44.63% | 46.37% | 47.83% | 46.72% | 48.25% | [{"date":"2019-12-31","value":92.5,"profit":true},{"date":"2020-12-31","value":96.12,"profit":true},{"date":"2021-12-31","value":99.13,"profit":true},{"date":"2022-12-31","value":96.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 4.82B | 4.67B | 4.50B | 4.28B | 4.45B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":96.93,"profit":true},{"date":"2021-12-31","value":93.33,"profit":true},{"date":"2022-12-31","value":88.93,"profit":true},{"date":"2023-12-31","value":92.42,"profit":true}] |
Operating Income | 2.80B | 3.05B | 3.20B | 2.80B | 433.00M | [{"date":"2019-12-31","value":87.46,"profit":true},{"date":"2020-12-31","value":95.47,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":87.46,"profit":true},{"date":"2023-12-31","value":13.54,"profit":true}] |
Total Non-Operating Income/Expense | (4.94B) | (8.42B) | (3.50B) | (6.83B) | (2.15B) | [{"date":"2019-12-31","value":-493900000000,"profit":false},{"date":"2020-12-31","value":-842200000000,"profit":false},{"date":"2021-12-31","value":-350200000000,"profit":false},{"date":"2022-12-31","value":-682800000000,"profit":false},{"date":"2023-12-31","value":-215200000000,"profit":false}] |
Pre-Tax Income | (1.26B) | (4.41B) | 658.00M | (3.06B) | (624.00M) | [{"date":"2019-12-31","value":-192.25,"profit":false},{"date":"2020-12-31","value":-669.6,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-465.81,"profit":false},{"date":"2023-12-31","value":-94.83,"profit":false}] |
Income Taxes | (278.00M) | (168.00M) | 211.00M | (638.00M) | (65.00M) | [{"date":"2019-12-31","value":-131.75,"profit":false},{"date":"2020-12-31","value":-79.62,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-302.37,"profit":false},{"date":"2023-12-31","value":-30.81,"profit":false}] |
Income After Taxes | (987.00M) | (4.24B) | 447.00M | (2.43B) | (559.00M) | [{"date":"2019-12-31","value":-220.81,"profit":false},{"date":"2020-12-31","value":-948.1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-542.95,"profit":false},{"date":"2023-12-31","value":-125.06,"profit":false}] |
Income From Continuous Operations | (987.00M) | (4.24B) | 447.00M | (2.41B) | (615.00M) | [{"date":"2019-12-31","value":-220.81,"profit":false},{"date":"2020-12-31","value":-948.1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-538.26,"profit":false},{"date":"2023-12-31","value":-137.58,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (999.00M) | (3.99B) | 417.00M | (2.35B) | (559.00M) | [{"date":"2019-12-31","value":-239.57,"profit":false},{"date":"2020-12-31","value":-956.83,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-564.27,"profit":false},{"date":"2023-12-31","value":-134.05,"profit":false}] |
EPS (Diluted) | 2.40 | 2.57 | 2.58 | 2.53 | 2.56 | [{"date":"2019-12-31","value":93.02,"profit":true},{"date":"2020-12-31","value":99.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.06,"profit":true},{"date":"2023-12-31","value":99.22,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
TEVA | |
---|---|
Cash Ratio | 0.22 |
Current Ratio | 0.89 |
Quick Ratio | 0.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TEVA | |
---|---|
ROA (LTM) | 4.84% |
ROE (LTM) | -9.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TEVA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.82 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 5.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TEVA | |
---|---|
Trailing PE | NM |
Forward PE | 5.59 |
P/S (TTM) | 0.99 |
P/B | 1.99 |
Price/FCF | 398 |
EV/R | 2.05 |
EV/Ebitda | 20.84 |
PEG | NM |
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potentia…
Teva unveils Aventrail, a trail running sandal with the fit of a shoe. Featuring W Strapping System, HYPER-COMF cushioning, and Spider Rubber® outsole for $145.
Teva, a division of Deckers Brands (NYSE: DECK), is continuing to push the boundaries in performance footwear, introducing the first-of-its-kind, trail running sandal built for an uninhibited run experience. Aventrail was created to bridge a gap in the trail running market between running sandals with minimal support and modern running shoes with underfoot innovation and cushion. Delivering the Jetzt den vollständigen Artikel lesen
The deal with the Israel Tax Authority resolves all pending litigation related to taxes payable for the years from 2008 to 2020
Teva Pharmaceutical Industries has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company''s taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end Jetzt den vollständigen Artikel lesen
Teva resolves $750M tax dispute with Israel, settles litigation for 2008-2020; no impact on 2024 outlook. Focus shifts to ''Pivot to Growth'' strategy. Read more.
Wearing sandals without arch support can cause pain and discomfort. Experts recommended these sandals with arch support from brands like Birkenstock, Vionic, Teva and more.
Teva Pharma Industries Ltd ADR (TEVA) share price today is $16.25
Yes, Indians can buy shares of Teva Pharma Industries Ltd ADR (TEVA) on Vested. To buy Teva Pharma Industries Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TEVA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Teva Pharma Industries Ltd ADR (TEVA) via the Vested app. You can start investing in Teva Pharma Industries Ltd ADR (TEVA) with a minimum investment of $1.
You can invest in shares of Teva Pharma Industries Ltd ADR (TEVA) via Vested in three simple steps:
The 52-week high price of Teva Pharma Industries Ltd ADR (TEVA) is $17.69. The 52-week low price of Teva Pharma Industries Ltd ADR (TEVA) is $7.42.
The price-to-earnings (P/E) ratio of Teva Pharma Industries Ltd ADR (TEVA) is NM
The price-to-book (P/B) ratio of Teva Pharma Industries Ltd ADR (TEVA) is 1.99
The dividend yield of Teva Pharma Industries Ltd ADR (TEVA) is 0.00%
The market capitalization of Teva Pharma Industries Ltd ADR (TEVA) is $18.40B
The stock symbol (or ticker) of Teva Pharma Industries Ltd ADR is TEVA